Nkgen BiotechNKGN

13F holders, Q1 2026 (March 31)
1holders
0new positions
0sold out
$0.07avg. 13F price*

At the end of Q1 2026, 1 institutions reported holding Nkgen Biotech Inc. (NKGN) in their 13F filings, unchanged from Q4 2025. 0 opened new positions and 0 sold out. The largest holder was Meteora Capital, LLC ($193K).

Company
Nkgen Biotech Inc.
CUSIP
65488A101
Latest filing quarter
Q2 2026

History

Number of 13F holders

0510152025 Q1 2024: 13Q1 2024Q2 2024: 17Q2 2024Q3 2024: 19Q3 2024Q4 2024: 25Q4 2024Q1 2025: 3Q1 2025Q3 2025: 1Q3 2025Q4 2025: 1Q4 2025Q1 2026: 1Q1 2026Q2 2026: 1Q2 2026

Total Exit/New Position Q4 2025 → Q1 2026

InstitutionsTotal Value
New Positions0$0
Exits0$0

Ownership 1 holders

Meteora Capital, LLC 0.01% No change 2,755,935 $193K

"% of holder's portfolio" is NKGN's weight in each manager's 13F, not the share of Nkgen Biotech Inc. the manager owns.